OLMA
Overvalued by 43.6% based on the discounted cash flow analysis.
Market cap | $285.32 Million |
---|---|
Enterprise Value | $212.56 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-2.2 |
Beta | 2.01 |
Outstanding Shares | 85,426,223 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -2.76 |
---|---|
PEG | 147.32 |
Price to Sales | - |
Price to Book Ratio | 1.04 |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | -1.49 |
Enterprise Value to Net Income | -2 |
Total Debt to Enterprise | -0.1 |
Debt to Equity | -0.06 |
No data
No data
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an o...